Fenretinide Treatment for Neural Injury and Neurodegeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neural diseases such as spinal cord injury (SCI) and amyotrophic lateral sclerosis (ALS) are limited in efficacy and associated with significant side effects, with no effective methods available to prevent or treat the progressive nature of these conditions.
Innovation Solution
The use of a retinoic acid derivative, specifically fenretinide, and its analogs, derivatives, prodrugs, or salts, administered to treat neural injury or neurodegenerative diseases by modulating polyunsaturated fatty acid levels, reducing inflammation, and attenuating oxidative stress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If methylprednisolone is administered for spinal cord injury treatment, then some therapeutic benefit is achieved, but serious side effects occur and efficacy is limited
Solution Approach 1:
The patent changes the chemical parameter from glucocorticosteroid (methylprednisolone) to retinoic acid derivative (fenretinide), fundamentally altering the therapeutic agent's molecular structure and mechanism of action to achieve better efficacy-safety profile
Solution Approach 2:
The patent employs fenretinide, a compound with established safety profile from cancer treatment, replacing the expensive and problematic methylprednisolone regimen, achieving comparable or superior therapeutic effects with fewer long-term consequences
2Duration of action of stationary object
If riluzole is administered for ALS treatment, then disease progression is slowed, but several side effects occur
Solution Approach 1:
The patent changes the therapeutic parameter from glutamate release inhibition (riluzole mechanism) to polyunsaturated fatty acid level modulation (fenretinide mechanism), addressing ALS pathology through a different biochemical pathway that reduces oxidative stress and inflammation
Solution Approach 2:
The patent introduces fenretinide as an intermediary substance that modulates fatty acid metabolism and reduces reactive oxygen species, serving as a mediator between the disease process and therapeutic outcome with a more favorable safety profile
3Reliability
If conventional pharmacological agents are used for neural diseases, then some treatment effect is achieved, but the progressive nature of diseases remains unaddressed
Solution Approach 1:
The patent applies fenretinide early in the disease course to prevent secondary injury cascades and neurodegeneration before they fully develop, addressing the progressive nature of neural diseases by intervening at the initial inflammatory and oxidative stress stages
Solution Approach 2:
The patent employs continuous fenretinide treatment that sustains protective effects against ongoing neurodegeneration, maintaining therapeutic pressure to counteract the progressive nature of diseases like ALS and spinal cord injury over extended periods
Data Source
AI summary
Compounds, methods, uses, compositions, kits and packages for the prevention and/or treatment of neural injury or a neurodegenerative disease, based on the use of a retinoic acid derivative, such as fenretinide, and/or analogs, derivatives, prodrugs, precursors thereof, and/or salts thereof, are described.